Whether Remdesivir Increases the Risk of Acute Kidney Injury (AKI) in Patients with COVID-19: A Systematic Review and Meta-Analysis

Abstract Background: Acute kidney injury (AKI) occurs among patients with COVID-19, it is also proved to be associated with in-hospital mortality. Remdesivir, an RNA polymerase inhibitor, has shown its antiviral activity in vitro and animal models. The adverse effect of Remdesivir especially AKI is the most common cause which lead to drug discontinuation. Whether Remdesivir increases the risk of AKI in patients with COVID-19 is not clear. We conducted a systematic review and meta-analysis to evaluate the incidence rate of AKI in hospitalized COVID-19 patients and whether Remdesivir increases the risk of AKI. Methods: A thorough search was carried out to find relevant studies in PubMed, medRxiv, and Web of Science from 1 Jan 2020 till 1 June 2020. 15135 COVID-19 patients and 981 COVID-19 patients using Remdesivir were included in our meta-analysis. Results: The pooled estimated incidence of AKI in all hospitalized COVID-19 patients was 12.0% (95% CI:9.0%-15.0%). According to our subgroup study, the incidence of AKI was associated with the age, disease severity and race of patients. The incidence of AKI in hospitalized COVID-19 patients using Remdesivir was 6% (95% CI: 3%-13%) with a total of 5 studies. Comparing with COVID-19 patients without Remdesivir treatment, Remdesivir treatment do not increase the risk of AKI in COVID-19 patients showing OR 0.80(95%CI: 0.44-1.46, P>0.05). Conclusions: We found out that AKI was not rare in hospitalized COVID-19 patients. The incidence of AKI was associated with age, disease severity and race. Remdesivir treatment did not increase the risk of AKI in hospitalized COVID-19 patients. Our meta-analysis may provide an evidence for future study that AKI is associated with the natural cause of COVID-19, not the adverse event after the usage of Remdesivir.

Download Full-text

Risk of antimicrobial-associated organ injury among the older adults: a systematic review and meta-analysis

BMC Geriatrics ◽

10.1186/s12877-021-02512-3 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Tichawona Chinzowu ◽

Sandipan Roy ◽

Prasad S. Nishtala

Keyword(s):

Systematic Review ◽

Older Adults ◽

Acute Kidney Injury ◽

Web Of Science ◽

Meta Analysis ◽

Adult Population ◽

Kidney Injury ◽

Organ Injury ◽

Funnel Plot ◽

General Adult Population

Abstract Background Older adults (aged 65 years and above) constitute the fastest growing population cohort in the western world. There is increasing evidence that the burden of infections disproportionately affects older adults, and hence this vulnerable population is frequently exposed to antimicrobials. There is currently no systematic review summarising the evidence for organ injury risk among older adults following antimicrobial exposure. This systematic review and meta-analysis examined the relationship between antimicrobial exposure and organ injury in older adults. Methodology We searched for original research articles in PubMed, Embase.com, Web of Science core collection, Web of Science BIOSIS citation index, Scopus, Cochrane Central Register of Controlled Trials, ProQuest, and PsycINFO databases, using key words in titles and abstracts, and using MeSH terms. We searched for all available articles up to 31 May 2021. After removing duplicates, articles were screened for inclusion into or exclusion from the study by two reviewers. The Newcastle-Ottawa scale was used to assess the risk of bias for cohort and case-control studies. We explored the heterogeneity of the included studies using the Q test and I2 test and the publication bias using the funnel plot and Egger’s test. The meta-analyses were performed using the OpenMetaAnalyst software. Results The overall absolute risks of acute kidney injury among older adults prescribed aminoglycosides, glycopeptides, and macrolides were 15.1% (95% CI: 12.8–17.3), 19.1% (95% CI: 15.4–22.7), and 0.3% (95% CI: 0.3–0.3), respectively. Only 3 studies reported antimicrobial associated drug-induced liver injury. Studies reporting on the association of organ injury and antimicrobial exposure by age or duration of treatment were too few to meta-analyse. The funnel plot and Egger’s tests did not indicate evidence of publication bias. Conclusion Older adults have a significantly higher risk of sustaining acute kidney injury when compared to the general adult population. Older adults prescribed aminoglycosides have a similar risk of acute kidney injury to the general adult population.

Download Full-text

Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19

10.21203/rs.3.rs-52615/v3 ◽

2021 ◽

Author(s):

Zhenjian Xu ◽

Ying Tang ◽

Qiuyan Huang ◽

Sha Fu ◽

Xiaomei Li ◽

...

Keyword(s):

Systematic Review ◽

Acute Kidney Injury ◽

Renal Replacement Therapy ◽

Hospital Mortality ◽

Continuous Renal Replacement Therapy ◽

Disease Severity ◽

Subgroup Analysis ◽

Web Of Science ◽

Kidney Injury ◽

Future Studies

Abstract Background: Acute kidney injury (AKI) occurs among patients with coronavirus disease-19 (COVID-19) and has also been indicated to be associated with in-hospital mortality. Remdesivir has been authorized for the treatment of COVID-19. We conducted a systematic review to evaluate the incidence of AKI in hospitalized COVID-19 patients. The incidence of AKI in different subgroups was also investigated.Methods: A thorough search was performed to find relevant studies in PubMed, Web of Science, medRxiv and EMBASE from 1 Jan 2020 until 1 June 2020. The systematic review was performed using the meta package in R (4.0.1).Results: A total of 16199 COVID-19 patients were included in our systematic review. The pooled estimated incidence of AKI in all hospitalized COVID-19 patients was 10.0% (95% CI: 7.0-12.0%). The pooled estimated proportion of COVID-19 patients who needed continuous renal replacement therapy (CRRT) was 4% (95% CI: 3-6%). According to our subgroup analysis, the incidence of AKI could be associated with age, disease severity and ethnicity. The incidence of AKI in hospitalized COVID-19 patients being treated with remdesivir was 7% (95% CI: 3-13%) in a total of 5 studies. Conclusion: We found that AKI was not rare in hospitalized COVID-19 patients. The incidence of AKI could be associated with age, disease severity and ethnicity. Remdesivir probably did not induce AKI in COVID-19 patients. Our systematic review provides evidence that AKI might be closely associated with SARS-CoV-2 infection, which should be investigated in future studies.

Download Full-text

The systemic review of subgroup analysis on the incidence of acute kidney injury(AKI) in patients with COVID-19

10.21203/rs.3.rs-52615/v2 ◽

2020 ◽

Author(s):

Zhenjian Xu ◽

Ying Tang ◽

Qiuyan Huang ◽

Sha Fu ◽

Xiaomei Li ◽

...

Keyword(s):

Systematic Review ◽

Acute Kidney Injury ◽

Renal Replacement Therapy ◽

Disease Severity ◽

Subgroup Analysis ◽

Web Of Science ◽

Kidney Injury ◽

Systemic Review ◽

Future Studies ◽

R Project

Abstract Background: Acute kidney injury (AKI) occurs among patients with Coronavirus disease-19 (COVID-19) and has also been proven to be associated with in-hospital mortality. Remdesivir has been authorized for the treatment of COVID-19 patients. We conducted a systematic review to evaluate the incidence of AKI in hospitalized COVID-19 patients. The incidence of AKI in different subgroups was also investigated. Method: A thorough search was carried out to find relevant studies in PubMed, Web of Science, medRxiv and EMBASE from 1 Jan 2020 until 1 June 2020. All systemic reviews of proportions were performed using the meta package for R project (4.0.1).Results: A total of 16199 COVID-19 patients were included in our systematic review. The pooled estimated incidence of AKI in all hospitalized COVID-19 patients was 10.0% (95% CI: 7.0-12.0%). The pooled estimated need for continuous renal replacement therapy (CRRT) in COVID-19 patients was 4% (95% CI: 3-6%). According to our subgroup analysis, the incidence of AKI could be associated with the age, disease severity and the ethnicity of the patients. The incidence of AKI in hospitalized COVID-19 patients being treated with remdesivir was 7% (95% CI: 3-13%) in a total of 5 studies.Conclusion: We found that AKI was not rare in hospitalized COVID-19 patients. The incidence of AKI could be associated with age, disease severity and ethnicity. Remdesivir probably not induced AKI in COVID-19 patients. Our systemic review provides evidence for future studies that AKI might be closely associated with SARS-CoV-2 infection.

Download Full-text

Systematic review and subgroup analysis of the incidence of acute kidney injury (AKI) in patients with COVID-19

BMC Nephrology ◽

10.1186/s12882-021-02244-x ◽

2021 ◽

Vol 22 (1) ◽

Author(s):

Zhenjian Xu ◽

Ying Tang ◽

Qiuyan Huang ◽

Sha Fu ◽

Xiaomei Li ◽

...

Keyword(s):

Systematic Review ◽

Acute Kidney Injury ◽

Renal Replacement Therapy ◽

Hospital Mortality ◽

Continuous Renal Replacement Therapy ◽

Disease Severity ◽

Subgroup Analysis ◽

Web Of Science ◽

Kidney Injury ◽

Future Studies

Abstract Background Acute kidney injury (AKI) occurs among patients with coronavirus disease-19 (COVID-19) and has also been indicated to be associated with in-hospital mortality. Remdesivir has been authorized for the treatment of COVID-19. We conducted a systematic review to evaluate the incidence of AKI in hospitalized COVID-19 patients. The incidence of AKI in different subgroups was also investigated. Methods A thorough search was performed to find relevant studies in PubMed, Web of Science, medRxiv and EMBASE from 1 Jan 2020 until 1 June 2020. The systematic review was performed using the meta package in R (4.0.1). Results A total of 16,199 COVID-19 patients were included in our systematic review. The pooled estimated incidence of AKI in all hospitalized COVID-19 patients was 10.0% (95% CI: 7.0–12.0%). The pooled estimated proportion of COVID-19 patients who needed continuous renal replacement therapy (CRRT) was 4% (95% CI: 3–6%). According to our subgroup analysis, the incidence of AKI could be associated with age, disease severity and ethnicity. The incidence of AKI in hospitalized COVID-19 patients being treated with remdesivir was 7% (95% CI: 3–13%) in a total of 5 studies. Conclusion We found that AKI was not rare in hospitalized COVID-19 patients. The incidence of AKI could be associated with age, disease severity and ethnicity. Remdesivir probably did not induce AKI in COVID-19 patients. Our systematic review provides evidence that AKI might be closely associated with SARS-CoV-2 infection, which should be investigated in future studies.

Download Full-text